• MorphoSys AG, of Martinsried, Germany, submitted a clinical trial application to start Phase I testing of MOR103, a HuCAL-derived antibody for rheumatoid arthritis. The company said it plans to reveal the target molecule of its lead antibody program MOR103 and additional information on the Phase I design in mid-January.